Search

Your search keyword '"ideal agent"' showing total 970 results

Search Constraints

Start Over You searched for: "ideal agent" Remove constraint "ideal agent" Publisher springer nature Remove constraint Publisher: springer nature
970 results on '"ideal agent"'

Search Results

2. Protective effects of ginsenosides on ulcerative colitis: a meta-analysis and systematic review to reveal the mechanisms of action.

3. A Reason to Know.

4. 5-Aminolevulinic acid increases boronophenylalanine uptake into glioma stem cells and may sensitize malignant glioma to boron neutron capture therapy.

5. Preclinical evidence for quercetin against inflammatory bowel disease: a meta-analysis and systematic review.

6. Demystifying Desert.

8. Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics.

9. Evaluation of Analgesic Efficacy of Dexmedetomidine as an Adjuvant to Local Anaesthesia in Maxillofacial Soft Tissue Injuries: A Prospective Randomised Clinical Trial.

10. An efficient tuning method for networked control systems.

11. PCN-Fe(III)-PTX nanoparticles for MRI guided high efficiency chemo-photodynamic therapy in pancreatic cancer through alleviating tumor hypoxia.

12. Knowledge-based adaptive agents for manufacturing domains.

13. A virtual scalable model of the Hepatic Lobule for acetaminophen hepatotoxicity prediction.

14. A Rational Agent With Our Evidence.

15. The child the apple eats: processing of argument structure in Mandarin verb-final sentences.

16. Clumped isotopes reveal relationship between mussel growth and river discharge.

17. The Spectrum of Liability to Defensive Harm and the Case of Child Soldiers.

18. Defending Pure Moral Deference: an Argument from Rationality.

19. Hume's liberalism based on Scottish jurisprudence.

20. Naturalistic Moral Realism and Moral Disagreement: David Copp's Account.

21. Bulking Agents in the Management of Urinary Incontinence: Dead or Alive?

22. Should We Embrace Impossible Worlds Due to the Flaws of Normal Modal Logic?

23. Opinion Dynamics with Preference Matching: How the Desire to Meet Facilitates Opinion Exchange.

24. Effect of Oral Mifepristone on Modified Bishop's Score in Term Pregnancy.

25. Extension of patch residence time of a biocontrol agent by selective breeding contributes to its early establishment and suppression of a pest population.

26. Direct Oral Anticoagulants: Navigating Through Clinical Challenges.

27. Recent contributions of molecular population genetic and phylogenetic studies to classic biological control of weeds.

28. Desert for Wrongdoing.

29. Learning to Network.

30. Probabilities in Decision Rules.

31. Crossover from gas-like to liquid-like molecular diffusion in a simple supercritical fluid.

33. Bridge Principles and Epistemic Norms.

34. Higher-Order Evidence and the Dynamics of Self-Location: An Accuracy-Based Argument for Calibrationism.

35. Expanding a peptide-covalent probe hybrid for PET imaging of S. aureus driven focal infections.

36. The Mirage of Motivation Reason Internalism.

37. Consent for Medical Treatment: What is 'Reasonable'?

38. Pipeline Therapies for Gout.

39. Fortune.

40. A Review of Fire-Extinguishing Agents and Fire Suppression Strategies for Lithium-Ion Batteries Fire.

41. Current and investigational anti-obesity drugs help reduce weight and offer additional benefits, but more effective options are needed.

42. Pharmacogenetics of nonsteroidal anti-inflammatory drugs.

43. Pleurodesis by erythromycin, tetracycline, AerosilTM 200, and erythromycin plus AerosilTM 200 in a rat model: a preliminary study.

44. The design of motivational agents and avatars.

45. Utility and framing.

46. Prevention of colorectal cancer by combining early detection and chemoprevention.

47. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.

48. Desirable Therapeutic Characteristics of an Optimal Antihypertensive Agent.

49. Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis.

50. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.

Catalog

Books, media, physical & digital resources